165 related articles for article (PubMed ID: 37467967)
21. [Progress of PD-1/PD-L1 inhibitors in the treatment of small-cell lung cancer].
Zhang SY; Wang Y
Zhonghua Zhong Liu Za Zhi; 2021 Jan; 43(1):98-103. PubMed ID: 33472320
[TBL] [Abstract][Full Text] [Related]
22. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Dafni U; Tsourti Z; Vervita K; Peters S
Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
[TBL] [Abstract][Full Text] [Related]
23. Carcinomatous meningitis during systematic chemotherapy in a patient with advanced small-cell neuroendocrine carcinoma of the uterine cervix.
Watanabe Y; Nakai H; Imaoka I; Murakami T; Hoshiai H
J Obstet Gynaecol Res; 2012 Jan; 38(1):336-9. PubMed ID: 21917069
[TBL] [Abstract][Full Text] [Related]
24. PD-L1 expression and immune stromal features in HPV-independent cervical adenocarcinoma.
Song F; Jia M; Yu S; Cao L; Sun PL; Gao H
Histopathology; 2021 Nov; 79(5):861-871. PubMed ID: 34156708
[TBL] [Abstract][Full Text] [Related]
25. Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer.
Wu Z; Man S; Sun R; Li Z; Wu Y; Zuo D
Int Immunopharmacol; 2020 Aug; 85():106613. PubMed ID: 32450531
[TBL] [Abstract][Full Text] [Related]
26. Expression and Significance of Immune Checkpoints in Clear Cell Carcinoma of the Uterine Cervix.
Zong L; Zhang Q; Zhou Y; Kong Y; Yu S; Chen J; Zhang Y; Xiang Y
J Immunol Res; 2020; 2020():1283632. PubMed ID: 32322590
[TBL] [Abstract][Full Text] [Related]
27. Programmed death-ligand 1 expression in human papillomavirus-independent cervical adenocarcinoma and its prognostic significance.
Chen L; Lucas E; Zhang X; Liu Q; Zhuang Y; Lin W; Chen H; Zhou F
Histopathology; 2022 Jan; 80(2):338-347. PubMed ID: 34455625
[TBL] [Abstract][Full Text] [Related]
28. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
Poulose JV; Kainickal CT
World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
[TBL] [Abstract][Full Text] [Related]
29. PD-L1, PARP1, and MMRs as potential therapeutic biomarkers for neuroendocrine cervical cancer.
Ji X; Sui L; Song K; Lv T; Zhao H; Yao Q
Cancer Med; 2021 Jul; 10(14):4743-4751. PubMed ID: 34076351
[TBL] [Abstract][Full Text] [Related]
30. Balstilimab and other immunotherapy for recurrent and metastatic cervical cancer.
Bose CK
Med Oncol; 2022 Jan; 39(4):47. PubMed ID: 35092506
[TBL] [Abstract][Full Text] [Related]
31. Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status.
Yang W; Lu YP; Yang YZ; Kang JR; Jin YD; Wang HW
J Obstet Gynaecol Res; 2017 Oct; 43(10):1602-1612. PubMed ID: 28833798
[TBL] [Abstract][Full Text] [Related]
32. First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data.
Boussageon M; Swalduz A; Chouaïd C; Bylicki O
BioDrugs; 2022 Mar; 36(2):137-151. PubMed ID: 35147894
[TBL] [Abstract][Full Text] [Related]
33. A potential role for intensive chemotherapy in the treatment of small cell neuroendocrine tumors of the cervix.
Lewandowski GS; Copeland LJ
Gynecol Oncol; 1993 Jan; 48(1):127-31. PubMed ID: 8380787
[TBL] [Abstract][Full Text] [Related]
34. Small cell neuroendocrine carcinomas of the lung do not harbor high-risk human papillomavirus.
Hartley CP; Steinmetz HB; Memoli VA; Tafe LJ
Hum Pathol; 2015 Apr; 46(4):577-82. PubMed ID: 25661244
[TBL] [Abstract][Full Text] [Related]
35. Durvalumab for the treatment of non-small cell lung cancer.
Murakami S
Expert Rev Anticancer Ther; 2019 Dec; 19(12):1009-1016. PubMed ID: 31782989
[No Abstract] [Full Text] [Related]
36. Pembrolizumab in recurrent advanced cervical squamous carcinoma.
Martínez P; Del Campo JM
Immunotherapy; 2017 May; 9(6):467-470. PubMed ID: 28399693
[TBL] [Abstract][Full Text] [Related]
37. Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition.
Minion LE; Tewari KS
Gynecol Oncol; 2018 Mar; 148(3):609-621. PubMed ID: 29666026
[TBL] [Abstract][Full Text] [Related]
38. Programmed cell death protein 1/programmed death ligand 1 but not HER2 is a potential therapeutic target in gastric neuroendocrine carcinoma.
Yamashita S; Abe H; Kunita A; Yamashita H; Seto Y; Ushiku T
Histopathology; 2021 Feb; 78(3):381-391. PubMed ID: 32767778
[TBL] [Abstract][Full Text] [Related]
39. Nocardia Rubra Cell Wall Skeleton Up-Regulates T Cell Subsets and Inhibits PD-1/PD-L1 Pathway to Promote Local Immune Status of Patients With High-Risk Human Papillomavirus Infection and Cervical Intraepithelial Neoplasia.
Chen W; Zhang Y; Zhao C; Shao S; Zhang Y; Li X; Bai X; Guo Q; Liu Q; Tang J; Zhang L
Front Immunol; 2020; 11():612547. PubMed ID: 33552075
[TBL] [Abstract][Full Text] [Related]
40. Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia.
Yang W; Song Y; Lu YL; Sun JZ; Wang HW
Immunology; 2013 Aug; 139(4):513-22. PubMed ID: 23521696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
